IL158107A0 - Human papillomaviruses vaccine - Google Patents

Human papillomaviruses vaccine

Info

Publication number
IL158107A0
IL158107A0 IL15810700A IL15810700A IL158107A0 IL 158107 A0 IL158107 A0 IL 158107A0 IL 15810700 A IL15810700 A IL 15810700A IL 15810700 A IL15810700 A IL 15810700A IL 158107 A0 IL158107 A0 IL 158107A0
Authority
IL
Israel
Prior art keywords
vaccine
human papillomaviruses
papillomaviruses
human
papillomaviruses vaccine
Prior art date
Application number
IL15810700A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of IL158107A0 publication Critical patent/IL158107A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09C—RECLAMATION OF CONTAMINATED SOIL
    • B09C1/00—Reclamation of contaminated soil
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D3/00—Improving or preserving soil or rock, e.g. preserving permafrost soil
    • E02D3/11—Improving or preserving soil or rock, e.g. preserving permafrost soil by thermal, electrical or electro-chemical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Structural Engineering (AREA)
  • Environmental & Geological Engineering (AREA)
  • Soil Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Paleontology (AREA)
  • Genetics & Genomics (AREA)
  • Civil Engineering (AREA)
  • Agronomy & Crop Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mining & Mineral Resources (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL15810700A 1999-09-07 2000-09-07 Human papillomaviruses vaccine IL158107A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9921146A GB9921146D0 (en) 1999-09-07 1999-09-07 Novel composition
PCT/EP2000/008784 WO2001017551A2 (en) 1999-09-07 2000-09-07 Combined vaccine compositions

Publications (1)

Publication Number Publication Date
IL158107A0 true IL158107A0 (en) 2004-03-28

Family

ID=10860520

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15810700A IL158107A0 (en) 1999-09-07 2000-09-07 Human papillomaviruses vaccine
IL14845600A IL148456A0 (en) 1999-09-07 2000-09-07 Combined vaccine compositions
IL158107A IL158107A (en) 1999-09-07 2003-09-25 Vaccine for human papillomavirus

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL14845600A IL148456A0 (en) 1999-09-07 2000-09-07 Combined vaccine compositions
IL158107A IL158107A (en) 1999-09-07 2003-09-25 Vaccine for human papillomavirus

Country Status (33)

Country Link
US (3) US6936255B1 (sv)
EP (3) EP1210113B1 (sv)
JP (2) JP4689910B2 (sv)
KR (2) KR100594668B1 (sv)
CN (2) CN100389824C (sv)
AR (1) AR025502A1 (sv)
AT (2) ATE312624T1 (sv)
AU (1) AU766494B2 (sv)
BR (1) BR0014171A (sv)
CA (2) CA2384064C (sv)
CO (1) CO5280045A1 (sv)
CY (2) CY1107457T1 (sv)
CZ (2) CZ302811B6 (sv)
DE (2) DE60027029T2 (sv)
DK (2) DK1210113T3 (sv)
ES (2) ES2253636T3 (sv)
GB (1) GB9921146D0 (sv)
GC (1) GC0000201A (sv)
HK (2) HK1048435B (sv)
HU (2) HU228687B1 (sv)
IL (3) IL158107A0 (sv)
MX (1) MXPA02002484A (sv)
MY (2) MY130084A (sv)
NO (3) NO332800B1 (sv)
NZ (2) NZ517621A (sv)
PL (2) PL201767B1 (sv)
PT (1) PT1210113E (sv)
SG (1) SG110072A1 (sv)
SI (2) SI1410805T1 (sv)
TR (1) TR200200607T2 (sv)
TW (1) TWI258374B (sv)
WO (1) WO2001017551A2 (sv)
ZA (2) ZA200306402B (sv)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DE60126737T2 (de) * 2001-03-23 2007-11-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003232951B2 (en) † 2002-05-17 2009-07-23 University Of Cape Town Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles.
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EA200701633A1 (ru) * 2002-12-20 2007-12-28 Глаксосмитклайн Байолоджикалс С.А. Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
CN100418577C (zh) * 2002-12-20 2008-09-17 葛兰素史密丝克莱恩生物有限公司 Hpv-16和hpv-18l1vlp疫苗
CN100355453C (zh) * 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
WO2004084938A1 (en) 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
BRPI0512042B8 (pt) * 2004-06-16 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, uso de uma composição ou vacina, método para produzir uma composição imunogênica, e, uso de vlps ou capsômeros de hpv 16 e 18 com vlps ou capsômeros de pelo menos um outro hpv do tipo causador de câncer
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US20090214592A1 (en) * 2005-02-16 2009-08-27 O'hagan Derek Adjuvant composition comprising aluminium phosphate and 3D-MPL
JP4182074B2 (ja) 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
CA2601022C (en) * 2005-03-23 2023-03-07 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
KR20080005583A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
MX2007013472A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
JP5394750B2 (ja) 2005-12-29 2014-01-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 多価ｐｃｖ２免疫原性組成物及び当該組成物を製造する方法
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
US20090246220A1 (en) * 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
DK2068918T4 (da) 2006-09-26 2024-09-02 Access To Advanced Health Inst Vaccinesammensætning omfattende syntetisk adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7709010B2 (en) 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
KR20150090285A (ko) * 2007-06-26 2015-08-05 고에키자이단호진 휴먼 사이언스 신코우자이단 고리스크군 인간 파필로마 바이러스에 대한 교차성 중화 항체를 유도하는 백신 항원
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
SI2318042T1 (sl) * 2008-07-31 2014-12-31 Glaxosmithkline Biologicals S.A. Cepivo proti HPV
EP3590533A1 (en) 2009-05-22 2020-01-08 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP3124491B1 (en) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
KR101181907B1 (ko) 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
EA022213B1 (ru) * 2009-06-25 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
JP2011251963A (ja) * 2010-05-28 2011-12-15 Coley Pharmaceutical Group Inc 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
DK2609428T3 (en) * 2010-08-27 2016-05-17 Intervet Int Bv STRENGTH TEST FOR VACCINE FORMULATIONS
CN102008721A (zh) * 2010-11-16 2011-04-13 浙江大学 一种hpv多肽/dc混合疫苗及其制备
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
AU2012272788B2 (en) * 2011-06-24 2016-10-20 Merck Sharp & Dohme Llc HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
EP2726097A4 (en) * 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR102411781B1 (ko) 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 단일 바이알 백신 제형
CN109804075A (zh) 2016-08-01 2019-05-24 威斯塔解剖学和生物学研究所 用于疫苗应用的复制缺陷型腺病毒载体的组合物和方法
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
GB201821207D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
AU2020283768A1 (en) 2019-05-25 2021-12-23 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
CN110576034B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复方法
CN110652980B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复剂
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
CN114681602B (zh) * 2020-12-25 2023-12-01 中国食品药品检定研究院 一种双价人乳头瘤病毒疫苗

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000017I1 (de) * 1991-07-19 2007-07-26 Univ Queensland Impfstoffe gegen Papillomavirus
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
PL178578B1 (pl) * 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
AU4727296A (en) * 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
CA2242200A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Toxoplasma gondii antigen tg20
TR199801531T2 (xx) * 1996-02-09 1998-10-21 Smithkline Beecham Biologicals S.A. Zoster vir�s geni ve �r�n�ne kar�� a��lar.
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
KR20010041629A (ko) * 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
US6500284B1 (en) 1998-06-10 2002-12-31 Suraltech, Inc. Processes for continuously producing fine grained metal compositions and for semi-solid forming of shaped articles
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
NO2012016I1 (no) 2012-10-15
PL201264B1 (pl) 2009-03-31
KR20020027630A (ko) 2002-04-13
NZ527560A (en) 2004-12-24
AU766494B2 (en) 2003-10-16
TW200408405A (en) 2004-06-01
DE60024893D1 (de) 2006-01-19
DE60027029D1 (de) 2006-05-18
DK1410805T3 (da) 2006-04-18
HK1048435A1 (en) 2003-04-04
SI1210113T1 (sl) 2006-08-31
EP1410805B1 (en) 2005-12-14
HU229099B1 (en) 2013-07-29
NO331825B1 (no) 2012-04-10
HK1064958A1 (en) 2005-02-08
GC0000201A (en) 2006-03-29
NO2012016I2 (no) 2012-10-08
DE60027029T2 (de) 2006-10-19
DE60024893T2 (de) 2006-07-06
US20040126394A1 (en) 2004-07-01
US6936255B1 (en) 2005-08-30
EP1769806A3 (en) 2007-10-24
GB9921146D0 (en) 1999-11-10
US7101560B2 (en) 2006-09-05
CA2384064C (en) 2010-06-01
CO5280045A1 (es) 2003-05-30
ATE312624T1 (de) 2005-12-15
CY1107457T1 (el) 2012-12-19
TR200200607T2 (tr) 2002-06-21
WO2001017551A2 (en) 2001-03-15
AU7775100A (en) 2001-04-10
BR0014171A (pt) 2002-05-21
NO20033715L (no) 2002-04-30
PL201767B1 (pl) 2009-05-29
EP1210113B1 (en) 2006-03-29
HU0303215D0 (en) 2003-11-28
ZA200201810B (en) 2004-05-26
HUP0202804A2 (hu) 2002-12-28
NO20021116L (no) 2002-04-30
US7220551B2 (en) 2007-05-22
HUP0303215A3 (en) 2008-04-28
MY130084A (en) 2007-05-31
PL354039A1 (en) 2003-12-15
CZ302811B6 (cs) 2011-11-23
KR100594668B1 (ko) 2006-06-30
IL148456A0 (en) 2002-09-12
JP2003508495A (ja) 2003-03-04
JP2004067696A (ja) 2004-03-04
CA2384064A1 (en) 2001-03-15
HUP0202804A3 (en) 2004-08-30
CN1618465A (zh) 2005-05-25
CA2443214C (en) 2006-03-21
EP1210113A2 (en) 2002-06-05
ATE321569T1 (de) 2006-04-15
NO20033715D0 (no) 2003-08-21
ZA200306402B (en) 2004-08-02
SG110072A1 (en) 2005-04-28
HU228687B1 (en) 2013-05-28
CZ2002843A3 (cs) 2002-08-14
IL158107A (en) 2008-11-03
NO20021116D0 (no) 2002-03-06
NZ517621A (en) 2003-09-26
ES2253636T3 (es) 2006-06-01
CN1325117C (zh) 2007-07-11
AR025502A1 (es) 2002-11-27
NO332800B1 (no) 2013-01-14
ES2261243T3 (es) 2006-11-16
CN1387443A (zh) 2002-12-25
CN100389824C (zh) 2008-05-28
SI1410805T1 (sl) 2006-04-30
CY1106090T1 (el) 2011-06-08
PT1210113E (pt) 2006-07-31
HK1048435B (zh) 2007-01-05
US20060280756A1 (en) 2006-12-14
WO2001017551A3 (en) 2001-09-27
MXPA02002484A (es) 2002-08-28
MY142842A (en) 2011-01-14
KR20030087081A (ko) 2003-11-12
TWI258374B (en) 2006-07-21
EP1769806A2 (en) 2007-04-04
KR100557665B1 (ko) 2006-03-06
EP1410805A1 (en) 2004-04-21
CA2443214A1 (en) 2001-03-15
JP4689910B2 (ja) 2011-06-01
DK1210113T3 (da) 2006-07-03

Similar Documents

Publication Publication Date Title
IL158107A0 (en) Human papillomaviruses vaccine
IL145043A0 (en) Vaccine
HUS1300072I1 (hu) Vakcina
HUP0202885A3 (en) Vaccines
GB9915414D0 (en) Medical use
GB9901254D0 (en) Vaccines
GB9915204D0 (en) Vaccine
HUP0202770A3 (en) Human papilloma virus vaccine
GB9907965D0 (en) Medical use
GB9906437D0 (en) Vaccine
EP1194439A4 (en) EAG2 OF HUMAN ORIGIN
GB9925379D0 (en) Medical use
GB9913327D0 (en) Vaccine
GB9911823D0 (en) New vaccine formulations
GB9922825D0 (en) Medical use
GB9922700D0 (en) Vaccine
GB9909072D0 (en) Vaccine
GB9925619D0 (en) Vaccine
GB9915106D0 (en) Vaccine
GB9922703D0 (en) Vaccine
GB9927336D0 (en) Vaccine
GB9919260D0 (en) Vaccine
GB9916677D0 (en) Vaccine
GB9915205D0 (en) Vaccine
GB9922701D0 (en) Vaccine